X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALKEM LABORATORIES   MYLAN
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
MYLAN
Dec-14
ALKEM LABORATORIES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,5893,806-   
Low Rs1,2322,682-   
Sales per share (Unadj.) Rs417.51,303.0-  
Earnings per share (Unadj.) Rs56.3157.0-  
Cash flow per share (Unadj.) Rs64.7252.7-  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.9647.7-  
Shares outstanding (eoy) m119.57378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x3.42.5 135.7%   
Avg P/E ratio x25.120.7 121.2%  
P/CF ratio (eoy) x21.812.8 169.8%  
Price / Book Value ratio x4.85.0 96.1%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6531,227,466 13.7%   
No. of employees `000NA25.0 0.0%   
Total wages/salary Rs m9,1710-   
Avg. sales/employee Rs ThNM19,720.0-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM2,375.6-  
INCOME DATA
Net Sales Rs m49,915492,999 10.1%  
Other income Rs m1,645-2,874 -57.2%   
Total revenues Rs m51,561490,126 10.5%   
Gross profit Rs m8,482122,611 6.9%  
Depreciation Rs m1,00636,209 2.8%   
Interest Rs m67121,265 3.2%   
Profit before tax Rs m8,45162,264 13.6%   
Minority Interest Rs m-114-255 44.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6062,618 61.3%   
Profit after tax Rs m6,73159,390 11.3%  
Gross profit margin %17.024.9 68.3%  
Effective tax rate %19.04.2 451.9%   
Net profit margin %13.512.0 111.9%  
BALANCE SHEET DATA
Current assets Rs m27,062433,411 6.2%   
Current liabilities Rs m15,324338,841 4.5%   
Net working cap to sales %23.519.2 122.6%  
Current ratio x1.81.3 138.1%  
Inventory Days Days6778 85.2%  
Debtors Days Days41107 38.5%  
Net fixed assets Rs m12,610114,054 11.1%   
Share capital Rs m23917,434 1.4%   
"Free" reserves Rs m34,4900-   
Net worth Rs m35,027245,069 14.3%   
Long term debt Rs m1,212366,109 0.3%   
Total assets Rs m54,387987,116 5.5%  
Interest coverage x13.63.9 346.3%   
Debt to equity ratio x01.5 2.3%  
Sales to assets ratio x0.90.5 183.8%   
Return on assets %13.68.2 166.6%  
Return on equity %19.224.2 79.3%  
Return on capital %24.913.6 182.4%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Net fx Rs m3,5520-   
CASH FLOW
From Operations Rs m7,25964,805 11.2%  
From Investments Rs m1,864-51,107 -3.6%  
From Financial Activity Rs m-9,273-17,076 54.3%  
Net Cashflow Rs m-150-3,378 4.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 63.86 Rs / USD

Compare ALKEM LABORATORIES With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ALKEM LABORATORIES With: SUVEN LIFE  PANACEA BIOTECH  J.B.CHEMICALS  DR. REDDYS LAB  WOCKHARDT LTD.  



Today's Market

Sensex Surges 400 Points; HDFC Twins Up 3%(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading near all-time high levels.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 18, 2018 03:33 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - PLETHICO PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS